Eli Lilly (LLY)
(Delayed Data from NYSE)
$884.48 USD
-1.46 (-0.16%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $881.52 -2.96 (-0.33%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Eli Lilly and Company falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,928 | 2,212 | 3,909 | 3,681 | 2,439 |
Receivables | 11,336 | 8,559 | 8,127 | 6,929 | 5,542 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,773 | 4,310 | 3,886 | 3,980 | 3,191 |
Other Current Assets | 5,690 | 2,954 | 2,531 | 2,872 | 2,539 |
Total Current Assets | 25,727 | 18,035 | 18,452 | 17,462 | 13,710 |
Net Property & Equipment | 12,914 | 10,144 | 8,985 | 8,682 | 7,873 |
Investments & Advances | 3,052 | 2,902 | 3,213 | 2,967 | 1,962 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 5,477 | 2,793 | 2,489 | 2,830 | 2,573 |
Intangibles | 11,846 | 11,280 | 11,584 | 11,217 | 10,297 |
Deposits & Other Assets | 4,990 | 4,337 | 4,083 | 3,475 | 2,339 |
Total Assets | 64,006 | 49,490 | 48,806 | 46,633 | 39,286 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 6,905 | 1,501 | 0 | 9 | 1,499 |
Accounts Payable | 2,599 | 1,931 | 1,671 | 1,607 | 1,405 |
Current Portion Long-Term Debt | 0 | 0 | 1,538 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 475 | 127 | 495 | 161 |
Other Current Liabilities | 17,790 | 13,231 | 11,717 | 10,371 | 8,710 |
Total Current Liabilities | 27,293 | 17,138 | 15,053 | 12,482 | 11,775 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 87 | 1,734 | 2,100 | 2,188 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18,321 | 14,738 | 15,346 | 16,587 | 13,818 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7,529 | 6,751 | 7,518 | 9,640 | 8,320 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53,143 | 38,714 | 39,651 | 40,808 | 36,587 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 594 | 594 | 596 | 598 | 599 |
Capital Surplus | 7,250 | 6,921 | 6,833 | 6,779 | 6,685 |
Retained Earnings | 10,312 | 10,043 | 8,959 | 7,830 | 4,920 |
Other Equity | -7,248 | -6,732 | -7,181 | -9,326 | -9,445 |
Treasury Stock | 44 | 51 | 53 | 56 | 61 |
Total Shareholder's Equity | 10,864 | 10,775 | 9,155 | 5,825 | 2,699 |
Total Liabilities & Shareholder's Equity | 64,006 | 49,490 | 48,806 | 46,633 | 39,286 |
Total Common Equity | 10,864 | 10,775 | 9,155 | 5,825 | 2,699 |
Shares Outstanding | 949.30 | 950.10 | 956.50 | 956.50 | 960.10 |
Book Value Per Share | 11.44 | 11.34 | 9.57 | 6.09 | 2.81 |
Fiscal Year End for Eli Lilly and Company falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3,364 | 2,586 | 2,928 | 2,494 | 2,829 |
Receivables | 13,079 | 10,014 | 11,336 | 10,364 | 9,171 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6,482 | 6,102 | 5,773 | 4,901 | 4,799 |
Other Current Assets | 7,280 | 6,487 | 5,690 | 5,248 | 4,532 |
Total Current Assets | 30,204 | 25,189 | 25,727 | 23,007 | 21,332 |
Net Property & Equipment | 14,829 | 13,624 | 12,914 | 11,863 | 11,277 |
Investments & Advances | 2,878 | 3,087 | 3,052 | 2,692 | 2,745 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 6,655 | 5,634 | 5,477 | 4,575 | 3,806 |
Intangibles | 12,404 | 11,702 | 11,846 | 10,867 | 10,982 |
Deposits & Other Assets | 4,904 | 4,708 | 4,990 | 4,912 | 4,672 |
Total Assets | 71,875 | 63,944 | 64,006 | 57,916 | 54,814 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 5,162 | 1,652 | 6,905 | 2,245 | 662 |
Accounts Payable | 2,925 | 2,474 | 2,599 | 2,435 | 2,474 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 1,978 | 1,234 |
Other Current Liabilities | 19,035 | 14,473 | 17,790 | 15,341 | 14,545 |
Total Current Liabilities | 27,121 | 18,598 | 27,293 | 21,998 | 18,915 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 23,730 | 24,560 | 18,321 | 17,924 | 18,158 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7,388 | 7,529 | 6,686 | 6,591 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58,239 | 51,046 | 53,143 | 46,608 | 43,665 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 594 | 594 | 594 | 594 | 594 |
Capital Surplus | 7,214 | 7,010 | 7,250 | 7,160 | 6,949 |
Retained Earnings | 13,178 | 12,554 | 10,312 | 10,310 | 10,369 |
Other Equity | -7,318 | -7,228 | -7,248 | -6,711 | -6,716 |
Treasury Stock | 33 | 33 | 44 | 45 | 45 |
Total Shareholder's Equity | 13,636 | 12,897 | 10,864 | 11,307 | 11,149 |
Total Liabilities & Shareholder's Equity | 71,875 | 63,944 | 64,006 | 57,916 | 54,814 |
Total Common Equity | 13,636 | 12,897 | 10,864 | 11,307 | 11,149 |
Shares Outstanding | 950.40 | 950.40 | 949.30 | 949.30 | 949.20 |
Book Value Per Share | 14.35 | 13.57 | 11.44 | 11.91 | 11.75 |